nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimetrexate—Hepatotoxicity—Vemurafenib—melanoma	0.0291	0.0654	CcSEcCtD
Trimetrexate—DHFR—Fluoropyrimidine Activity—XRCC3—melanoma	0.0285	0.0515	CbGpPWpGaD
Trimetrexate—DHFR—Trans-sulfuration and one carbon metabolism—PHGDH—melanoma	0.028	0.0506	CbGpPWpGaD
Trimetrexate—DHFR—G1/S-Specific Transcription—E2F1—melanoma	0.0176	0.0317	CbGpPWpGaD
Trimetrexate—DHFR—E2F transcription factor network—TRRAP—melanoma	0.0167	0.0302	CbGpPWpGaD
Trimetrexate—DHFR—G1/S-Specific Transcription—PCNA—melanoma	0.0166	0.0299	CbGpPWpGaD
Trimetrexate—Hepatotoxicity—Dactinomycin—melanoma	0.0165	0.0369	CcSEcCtD
Trimetrexate—Hepatotoxicity—Carmustine—melanoma	0.0154	0.0346	CcSEcCtD
Trimetrexate—Hepatotoxicity—Temozolomide—melanoma	0.0149	0.0334	CcSEcCtD
Trimetrexate—Hypocalcaemia—Dactinomycin—melanoma	0.0139	0.0312	CcSEcCtD
Trimetrexate—DHFR—Fluoropyrimidine Activity—SMUG1—melanoma	0.0135	0.0244	CbGpPWpGaD
Trimetrexate—DHFR—E2F transcription factor network—TP73—melanoma	0.0135	0.0243	CbGpPWpGaD
Trimetrexate—DHFR—E2F transcription factor network—MCL1—melanoma	0.0135	0.0243	CbGpPWpGaD
Trimetrexate—DHFR—G1/S Transition—PKMYT1—melanoma	0.0125	0.0226	CbGpPWpGaD
Trimetrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—CUBN—melanoma	0.0121	0.0219	CbGpPWpGaD
Trimetrexate—Phosphatase alkaline increased—Temozolomide—melanoma	0.0115	0.0258	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—APAF1—melanoma	0.0108	0.0194	CbGpPWpGaD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—PKMYT1—melanoma	0.0105	0.019	CbGpPWpGaD
Trimetrexate—DHFR—E2F mediated regulation of DNA replication—E2F1—melanoma	0.0103	0.0187	CbGpPWpGaD
Trimetrexate—DHFR—Fluoropyrimidine Activity—ERCC2—melanoma	0.01	0.0181	CbGpPWpGaD
Trimetrexate—Hepatotoxicity—Docetaxel—melanoma	0.0099	0.0222	CcSEcCtD
Trimetrexate—DHFR—E2F mediated regulation of DNA replication—PCNA—melanoma	0.00974	0.0176	CbGpPWpGaD
Trimetrexate—Blood alkaline phosphatase increased—Temozolomide—melanoma	0.00959	0.0215	CcSEcCtD
Trimetrexate—Hyponatraemia—Carmustine—melanoma	0.00867	0.0195	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.00831	0.0186	CcSEcCtD
Trimetrexate—Blood bilirubin increased—Docetaxel—melanoma	0.00808	0.0181	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Docetaxel—melanoma	0.00764	0.0172	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—SKP2—melanoma	0.00754	0.0136	CbGpPWpGaD
Trimetrexate—Aspartate aminotransferase increased—Temozolomide—melanoma	0.00751	0.0169	CcSEcCtD
Trimetrexate—Neutropenia—Dactinomycin—melanoma	0.00745	0.0167	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Temozolomide—melanoma	0.00736	0.0165	CcSEcCtD
Trimetrexate—DHFR—E2F mediated regulation of DNA replication—RB1—melanoma	0.00732	0.0132	CbGpPWpGaD
Trimetrexate—Neutropenia—Carmustine—melanoma	0.00698	0.0157	CcSEcCtD
Trimetrexate—Fatigue—Vemurafenib—melanoma	0.00692	0.0155	CcSEcCtD
Trimetrexate—DHFR—Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation—AKT1—melanoma	0.0068	0.0123	CbGpPWpGaD
Trimetrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—FASN—melanoma	0.00675	0.0122	CbGpPWpGaD
Trimetrexate—Neutropenia—Temozolomide—melanoma	0.00674	0.0151	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Docetaxel—melanoma	0.00638	0.0143	CcSEcCtD
Trimetrexate—Body temperature increased—Vemurafenib—melanoma	0.00634	0.0142	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—SKP2—melanoma	0.0063	0.0114	CbGpPWpGaD
Trimetrexate—DHFR—Folate Metabolism—IL4—melanoma	0.00597	0.0108	CbGpPWpGaD
Trimetrexate—Asthenia—Vemurafenib—melanoma	0.00576	0.0129	CcSEcCtD
Trimetrexate—Pruritus—Vemurafenib—melanoma	0.00568	0.0127	CcSEcCtD
Trimetrexate—Hyponatraemia—Docetaxel—melanoma	0.00557	0.0125	CcSEcCtD
Trimetrexate—Anaemia—Bleomycin—melanoma	0.0055	0.0124	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—E2F1—melanoma	0.00547	0.00988	CbGpPWpGaD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—SKP2—melanoma	0.00531	0.00958	CbGpPWpGaD
Trimetrexate—Anaemia—Dactinomycin—melanoma	0.00513	0.0115	CcSEcCtD
Trimetrexate—Vomiting—Vemurafenib—melanoma	0.0051	0.0115	CcSEcCtD
Trimetrexate—Rash—Vemurafenib—melanoma	0.00506	0.0114	CcSEcCtD
Trimetrexate—Dermatitis—Vemurafenib—melanoma	0.00505	0.0113	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Docetaxel—melanoma	0.005	0.0112	CcSEcCtD
Trimetrexate—Confusional state—Bleomycin—melanoma	0.0049	0.011	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Docetaxel—melanoma	0.00489	0.011	CcSEcCtD
Trimetrexate—Anaemia—Carmustine—melanoma	0.0048	0.0108	CcSEcCtD
Trimetrexate—Nausea—Vemurafenib—melanoma	0.00477	0.0107	CcSEcCtD
Trimetrexate—Thrombocytopenia—Bleomycin—melanoma	0.00476	0.0107	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—E2F1—melanoma	0.00476	0.00859	CbGpPWpGaD
Trimetrexate—DHFR—Folate Metabolism—ICAM1—melanoma	0.00474	0.00856	CbGpPWpGaD
Trimetrexate—DHFR—E2F transcription factor network—CDK2—melanoma	0.00472	0.00853	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism of nitric oxide—AKT1—melanoma	0.00471	0.0085	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—REC8—melanoma	0.0047	0.00849	CbGpPWpGaD
Trimetrexate—Anaemia—Temozolomide—melanoma	0.00464	0.0104	CcSEcCtD
Trimetrexate—Convulsion—Carmustine—melanoma	0.0045	0.0101	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—PCNA—melanoma	0.00449	0.0081	CbGpPWpGaD
Trimetrexate—Neutropenia—Docetaxel—melanoma	0.00448	0.0101	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—ATM—melanoma	0.00448	0.00809	CbGpPWpGaD
Trimetrexate—Thrombocytopenia—Dactinomycin—melanoma	0.00444	0.00997	CcSEcCtD
Trimetrexate—Convulsion—Temozolomide—melanoma	0.00435	0.00977	CcSEcCtD
Trimetrexate—Confusional state—Carmustine—melanoma	0.00428	0.00961	CcSEcCtD
Trimetrexate—Thrombocytopenia—Carmustine—melanoma	0.00415	0.00933	CcSEcCtD
Trimetrexate—Confusional state—Temozolomide—melanoma	0.00413	0.00928	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—CDK2—melanoma	0.0041	0.00741	CbGpPWpGaD
Trimetrexate—Thrombocytopenia—Temozolomide—melanoma	0.00401	0.00901	CcSEcCtD
Trimetrexate—Feeling abnormal—Bleomycin—melanoma	0.00401	0.00899	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—E2F1—melanoma	0.00397	0.00717	CbGpPWpGaD
Trimetrexate—DHFR—Folate Metabolism—ALB—melanoma	0.00395	0.00714	CbGpPWpGaD
Trimetrexate—Fatigue—Dactinomycin—melanoma	0.00391	0.00878	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—RB1—melanoma	0.00388	0.00701	CbGpPWpGaD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—CDK4—melanoma	0.00388	0.007	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—INCENP—melanoma	0.00386	0.00697	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—PKMYT1—melanoma	0.00386	0.00697	CbGpPWpGaD
Trimetrexate—Body temperature increased—Bleomycin—melanoma	0.00384	0.00863	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—PCNA—melanoma	0.00375	0.00676	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Dactinomycin—melanoma	0.00374	0.00839	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CDKN2B—melanoma	0.00365	0.00659	CbGpPWpGaD
Trimetrexate—DHFR—Folate Metabolism—IFNG—melanoma	0.00361	0.00651	CbGpPWpGaD
Trimetrexate—Body temperature increased—Dactinomycin—melanoma	0.00358	0.00805	CcSEcCtD
Trimetrexate—DHFR—Fluoropyrimidine Activity—TP53—melanoma	0.00358	0.00647	CbGpPWpGaD
Trimetrexate—Fatigue—Temozolomide—melanoma	0.00353	0.00794	CcSEcCtD
Trimetrexate—Feeling abnormal—Carmustine—melanoma	0.0035	0.00785	CcSEcCtD
Trimetrexate—Asthenia—Bleomycin—melanoma	0.00349	0.00783	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—INCENP—melanoma	0.00345	0.00623	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—PKMYT1—melanoma	0.00345	0.00623	CbGpPWpGaD
Trimetrexate—Pruritus—Bleomycin—melanoma	0.00344	0.00772	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—CDK2—melanoma	0.00343	0.00619	CbGpPWpGaD
Trimetrexate—DHFR—E2F transcription factor network—CDKN2A—melanoma	0.00341	0.00616	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Temozolomide—melanoma	0.00338	0.00759	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—RB1—melanoma	0.00337	0.00609	CbGpPWpGaD
Trimetrexate—Body temperature increased—Carmustine—melanoma	0.00335	0.00753	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—E2F1—melanoma	0.00335	0.00604	CbGpPWpGaD
Trimetrexate—Asthenia—Dactinomycin—melanoma	0.00325	0.0073	CcSEcCtD
Trimetrexate—Body temperature increased—Temozolomide—melanoma	0.00324	0.00728	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—IL2—melanoma	0.0032	0.00579	CbGpPWpGaD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—PCNA—melanoma	0.00316	0.0057	CbGpPWpGaD
Trimetrexate—Vomiting—Bleomycin—melanoma	0.00309	0.00694	CcSEcCtD
Trimetrexate—Anaemia—Docetaxel—melanoma	0.00309	0.00693	CcSEcCtD
Trimetrexate—Rash—Bleomycin—melanoma	0.00306	0.00688	CcSEcCtD
Trimetrexate—Dermatitis—Bleomycin—melanoma	0.00306	0.00688	CcSEcCtD
Trimetrexate—Asthenia—Carmustine—melanoma	0.00304	0.00684	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—CDKN1B—melanoma	0.00302	0.00545	CbGpPWpGaD
Trimetrexate—DHFR—Folate Metabolism—NFKB1—melanoma	0.003	0.00542	CbGpPWpGaD
Trimetrexate—Asthenia—Temozolomide—melanoma	0.00294	0.00661	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—POT1—melanoma	0.00291	0.00525	CbGpPWpGaD
Trimetrexate—Pruritus—Temozolomide—melanoma	0.0029	0.00651	CcSEcCtD
Trimetrexate—Convulsion—Docetaxel—melanoma	0.00289	0.0065	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CDK2—melanoma	0.00289	0.00521	CbGpPWpGaD
Trimetrexate—Nausea—Bleomycin—melanoma	0.00289	0.00648	CcSEcCtD
Trimetrexate—Vomiting—Dactinomycin—melanoma	0.00288	0.00647	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—MDM2—melanoma	0.00288	0.00519	CbGpPWpGaD
Trimetrexate—Rash—Dactinomycin—melanoma	0.00286	0.00642	CcSEcCtD
Trimetrexate—DHFR—Disease—MYO7A—melanoma	0.00284	0.00512	CbGpPWpGaD
Trimetrexate—DHFR—G1/S Transition—RB1—melanoma	0.00282	0.00508	CbGpPWpGaD
Trimetrexate—DHFR—E2F transcription factor network—CDKN1A—melanoma	0.00279	0.00503	CbGpPWpGaD
Trimetrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—melanoma	0.00277	0.005	CbGpPWpGaD
Trimetrexate—Confusional state—Docetaxel—melanoma	0.00275	0.00617	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CDK4—melanoma	0.00273	0.00493	CbGpPWpGaD
Trimetrexate—Vomiting—Carmustine—melanoma	0.0027	0.00606	CcSEcCtD
Trimetrexate—Nausea—Dactinomycin—melanoma	0.00269	0.00605	CcSEcCtD
Trimetrexate—Rash—Carmustine—melanoma	0.00268	0.00601	CcSEcCtD
Trimetrexate—Dermatitis—Carmustine—melanoma	0.00267	0.006	CcSEcCtD
Trimetrexate—Thrombocytopenia—Docetaxel—melanoma	0.00267	0.00599	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—CDKN1B—melanoma	0.00263	0.00474	CbGpPWpGaD
Trimetrexate—Vomiting—Temozolomide—melanoma	0.00261	0.00585	CcSEcCtD
Trimetrexate—Rash—Temozolomide—melanoma	0.00259	0.0058	CcSEcCtD
Trimetrexate—Dermatitis—Temozolomide—melanoma	0.00258	0.0058	CcSEcCtD
Trimetrexate—Nausea—Carmustine—melanoma	0.00252	0.00566	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—CCND1—melanoma	0.0025	0.00452	CbGpPWpGaD
Trimetrexate—Nausea—Temozolomide—melanoma	0.00244	0.00547	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—CDKN1A—melanoma	0.00242	0.00437	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HS3ST5—melanoma	0.00241	0.00436	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—ACER3—melanoma	0.00238	0.00429	CbGpPWpGaD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—RB1—melanoma	0.00237	0.00428	CbGpPWpGaD
Trimetrexate—Fatigue—Docetaxel—melanoma	0.00235	0.00528	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—TNF—melanoma	0.00233	0.00421	CbGpPWpGaD
Trimetrexate—DHFR—E2F transcription factor network—MYC—melanoma	0.00231	0.00417	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Docetaxel—melanoma	0.00225	0.00505	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—CDKN1B—melanoma	0.00219	0.00396	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—UGT2B10—melanoma	0.00217	0.00392	CbGpPWpGaD
Trimetrexate—Body temperature increased—Docetaxel—melanoma	0.00216	0.00484	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CDKN2A—melanoma	0.00209	0.00377	CbGpPWpGaD
Trimetrexate—DHFR—Folate Metabolism—TP53—melanoma	0.00206	0.00372	CbGpPWpGaD
Trimetrexate—DHFR—G1/S Transition—CDKN1A—melanoma	0.00202	0.00365	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—HS3ST5—melanoma	0.00202	0.00365	CbGpPWpGaD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—MYC—melanoma	0.00201	0.00363	CbGpPWpGaD
Trimetrexate—Asthenia—Docetaxel—melanoma	0.00196	0.00439	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle, Mitotic—SKP2—melanoma	0.00195	0.00352	CbGpPWpGaD
Trimetrexate—Pruritus—Docetaxel—melanoma	0.00193	0.00433	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—IL6—melanoma	0.00188	0.0034	CbGpPWpGaD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CDKN1B—melanoma	0.00185	0.00334	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—AURKA—melanoma	0.00178	0.00322	CbGpPWpGaD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CCND1—melanoma	0.00176	0.00318	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—MLH1—melanoma	0.00176	0.00318	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—SKP2—melanoma	0.00174	0.00314	CbGpPWpGaD
Trimetrexate—Vomiting—Docetaxel—melanoma	0.00173	0.00389	CcSEcCtD
Trimetrexate—DHFR—Disease—CUL3—melanoma	0.00172	0.0031	CbGpPWpGaD
Trimetrexate—DHFR—Disease—TRRAP—melanoma	0.00172	0.0031	CbGpPWpGaD
Trimetrexate—Rash—Docetaxel—melanoma	0.00172	0.00386	CcSEcCtD
Trimetrexate—Dermatitis—Docetaxel—melanoma	0.00172	0.00386	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CDKN1A—melanoma	0.0017	0.00308	CbGpPWpGaD
Trimetrexate—DHFR—G1/S Transition—MYC—melanoma	0.00168	0.00303	CbGpPWpGaD
Trimetrexate—DHFR—Disease—AKR1B10—melanoma	0.00167	0.00302	CbGpPWpGaD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—melanoma	0.00165	0.00298	CbGpPWpGaD
Trimetrexate—Nausea—Docetaxel—melanoma	0.00162	0.00364	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—AURKA—melanoma	0.00159	0.00287	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—APEX1—melanoma	0.00155	0.00279	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PLCB4—melanoma	0.00153	0.00277	CbGpPWpGaD
Trimetrexate—DHFR—Disease—LUM—melanoma	0.00149	0.00269	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HPSE—melanoma	0.00146	0.00264	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—SLC6A11—melanoma	0.00144	0.0026	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIP4K2A—melanoma	0.00144	0.0026	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CUBN—melanoma	0.00143	0.00259	CbGpPWpGaD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—MYC—melanoma	0.00141	0.00255	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—MTAP—melanoma	0.0014	0.00253	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CSPG4—melanoma	0.00139	0.0025	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—APEX1—melanoma	0.00138	0.0025	CbGpPWpGaD
Trimetrexate—DHFR—Disease—RPS3—melanoma	0.00136	0.00246	CbGpPWpGaD
Trimetrexate—DHFR—Disease—SKI—melanoma	0.00134	0.00242	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CDKN2B—melanoma	0.00134	0.00242	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PHGDH—melanoma	0.00125	0.00225	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—LUM—melanoma	0.00125	0.00225	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—E2F1—melanoma	0.00123	0.00222	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—HPSE—melanoma	0.00122	0.00221	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—PRKCA—melanoma	0.0012	0.00217	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CUBN—melanoma	0.0012	0.00217	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CDKN2B—melanoma	0.0012	0.00216	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—SDHD—melanoma	0.00116	0.0021	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—BSG—melanoma	0.00116	0.0021	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CSPG4—melanoma	0.00116	0.0021	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—PCNA—melanoma	0.00116	0.00209	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GPAM—melanoma	0.00112	0.00203	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HDAC6—melanoma	0.00111	0.002	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—E2F1—melanoma	0.0011	0.00198	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—PRKCA—melanoma	0.00108	0.00194	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CDK2—melanoma	0.00106	0.00191	CbGpPWpGaD
Trimetrexate—DHFR—Disease—NPPA—melanoma	0.00105	0.0019	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—PCNA—melanoma	0.00104	0.00187	CbGpPWpGaD
Trimetrexate—DHFR—Disease—VCAN—melanoma	0.00103	0.00185	CbGpPWpGaD
Trimetrexate—DHFR—Disease—WNT5A—melanoma	0.00102	0.00184	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CDK4—melanoma	0.001	0.00181	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—TERT—melanoma	0.001	0.00181	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PLA2G6—melanoma	0.000956	0.00173	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CDK2—melanoma	0.000947	0.00171	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—ATM—melanoma	0.000899	0.00162	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CDK4—melanoma	0.000895	0.00162	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—RB1—melanoma	0.00087	0.00157	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—VCAN—melanoma	0.000858	0.00155	CbGpPWpGaD
Trimetrexate—DHFR—Disease—GAB2—melanoma	0.000817	0.00147	CbGpPWpGaD
Trimetrexate—Trimethoprim—ABCB1—melanoma	0.00081	1	CrCbGaD
Trimetrexate—DHFR—Disease—FASN—melanoma	0.000799	0.00144	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—RB1—melanoma	0.000778	0.0014	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HDAC2—melanoma	0.000768	0.00139	CbGpPWpGaD
Trimetrexate—DHFR—Disease—FOXO4—melanoma	0.000768	0.00139	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CXCR4—melanoma	0.000768	0.00139	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CDKN2A—melanoma	0.000765	0.00138	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CD44—melanoma	0.000759	0.00137	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CYP17A1—melanoma	0.000724	0.00131	CbGpPWpGaD
Trimetrexate—DHFR—Disease—AKT3—melanoma	0.000701	0.00127	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GNA11—melanoma	0.000684	0.00124	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CDKN2A—melanoma	0.000684	0.00123	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CDKN1B—melanoma	0.000677	0.00122	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—FASN—melanoma	0.000669	0.00121	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—MDM2—melanoma	0.000663	0.0012	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—SLC5A5—melanoma	0.000658	0.00119	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CCND1—melanoma	0.000646	0.00117	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GNAQ—melanoma	0.000636	0.00115	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CD44—melanoma	0.000636	0.00115	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CDKN1A—melanoma	0.000625	0.00113	CbGpPWpGaD
Trimetrexate—DHFR—Disease—ERBB4—melanoma	0.000619	0.00112	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CDKN2B—melanoma	0.000614	0.00111	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CYP1B1—melanoma	0.00061	0.0011	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CDKN1B—melanoma	0.000606	0.00109	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CD86—melanoma	0.000593	0.00107	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CCND1—melanoma	0.000578	0.00104	CbGpPWpGaD
Trimetrexate—DHFR—Disease—FGF1—melanoma	0.000575	0.00104	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CDKN1A—melanoma	0.000559	0.00101	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PDGFRA—melanoma	0.000557	0.00101	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PRKCA—melanoma	0.000552	0.000996	CbGpPWpGaD
Trimetrexate—DHFR—Disease—ERCC2—melanoma	0.000547	0.000988	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MAP2K2—melanoma	0.000539	0.000974	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—MAPK3—melanoma	0.000533	0.000962	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—MYC—melanoma	0.000518	0.000936	CbGpPWpGaD
Trimetrexate—DHFR—Disease—TERT—melanoma	0.000513	0.000926	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HLA-A—melanoma	0.000513	0.000926	CbGpPWpGaD
Trimetrexate—DHFR—Disease—RAC1—melanoma	0.000511	0.000924	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—MAPK1—melanoma	0.000507	0.000916	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—ABCB1—melanoma	0.000502	0.000906	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HIF1A—melanoma	0.000491	0.000886	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—MAPK3—melanoma	0.000477	0.00086	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—MYC—melanoma	0.000464	0.000837	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PRKCA—melanoma	0.000462	0.000834	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—ERCC2—melanoma	0.000458	0.000827	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—MAPK1—melanoma	0.000453	0.000819	CbGpPWpGaD
Trimetrexate—DHFR—Disease—NOS2—melanoma	0.000446	0.000806	CbGpPWpGaD
Trimetrexate—DHFR—Disease—NOTCH1—melanoma	0.000442	0.000798	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CD80—melanoma	0.000433	0.000782	CbGpPWpGaD
Trimetrexate—DHFR—Disease—APC—melanoma	0.000432	0.00078	CbGpPWpGaD
Trimetrexate—DHFR—Disease—KIT—melanoma	0.000432	0.00078	CbGpPWpGaD
Trimetrexate—DHFR—Disease—EGF—melanoma	0.000427	0.000771	CbGpPWpGaD
Trimetrexate—DHFR—Disease—BRAF—melanoma	0.000406	0.000733	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MAP2K1—melanoma	0.000382	0.00069	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—TP53—melanoma	0.000381	0.000687	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PIK3CD—melanoma	0.00038	0.000686	CbGpPWpGaD
Trimetrexate—DHFR—Disease—FGF2—melanoma	0.000364	0.000657	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIK3CG—melanoma	0.000362	0.000653	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PPARG—melanoma	0.000349	0.000631	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MDM2—melanoma	0.00034	0.000614	CbGpPWpGaD
Trimetrexate—DHFR—Disease—ERBB2—melanoma	0.000336	0.000606	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PIK3CB—melanoma	0.000331	0.000598	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CD4—melanoma	0.000331	0.000597	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PTGS2—melanoma	0.000328	0.000592	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIK3CD—melanoma	0.000318	0.000574	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—ALB—melanoma	0.000314	0.000567	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CDKN1B—melanoma	0.000311	0.000561	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CTNNB1—melanoma	0.000294	0.00053	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CDKN1A—melanoma	0.000287	0.000518	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PTEN—melanoma	0.000286	0.000517	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIK3CB—melanoma	0.000277	0.000501	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PTGS2—melanoma	0.000275	0.000496	CbGpPWpGaD
Trimetrexate—DHFR—Disease—STAT3—melanoma	0.000256	0.000462	CbGpPWpGaD
Trimetrexate—DHFR—Disease—NRAS—melanoma	0.000255	0.000461	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MAPK3—melanoma	0.000244	0.000441	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PTEN—melanoma	0.00024	0.000433	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MYC—melanoma	0.000238	0.000429	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MAPK1—melanoma	0.000233	0.00042	CbGpPWpGaD
Trimetrexate—DHFR—Disease—EGFR—melanoma	0.000233	0.00042	CbGpPWpGaD
Trimetrexate—DHFR—Disease—KRAS—melanoma	0.00022	0.000397	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PIK3CA—melanoma	0.000202	0.000364	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HRAS—melanoma	0.000187	0.000337	CbGpPWpGaD
Trimetrexate—DHFR—Disease—IL6—melanoma	0.000179	0.000323	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIK3CA—melanoma	0.000169	0.000305	CbGpPWpGaD
Trimetrexate—DHFR—Disease—AKT1—melanoma	0.000165	0.000298	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—AKT1—melanoma	0.000138	0.000249	CbGpPWpGaD
